Citations

Clear

17 citation(s) found for "Feldman, Jeremy".

Long‐term results of the DelIVery for Pulmonary Arterial Hypertension trial
Shapiro, Shelley, Tarver, James, Zwicke, Dianne, Feldman, Jeremy P., Chakinala, Murali M. , Frantz, Robert P. , Torres, Fernando , Bag, Remzi , Murphy, Jeffrey A. , Lautenbach, Amy A. , Morris, Marty , Peterson, Leigh , Frantz, Robert P , Gomberg‐Maitland, Mardi , Bourge, Robert C. , Waxman, Aaron B.

Mayo Clinic

Pulmonary Circulation | September 9, 2019 | Volume: 9 | Issue: 4 | Pages: 1-9

10.1177/2045894019878615 | PMID 31723407 Get It

BackgroundThe DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi‐center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a pump and a catheter for intravenous treprostinil. The study met its primary endpoint and demonstrated that the intravascular delivery system significantly reduced catheter related complications at 22,000 subject‐days of follow‐up compared with a predefined objective performance criterion. Here we summarize the results obtained during a 6.4‐year follow‐up period.MethodsThroughout study follow‐up, participants had clinic visits and medication refills at least every 12 weeks (dependent on the subjects’ dose). All adverse events and intravascular delivery system complications were evaluated and recorded.ResultsSixty pulmonary arterial hypertension subjects were followed post device implantation for approximately 282 patient‐years (range 87 days to 6.4 years). Of the 60 subjects, 14 died (1 related to intravascular delivery system pump failure), 2 withdrew after lung transplants, and 2 withdrew due to pump pocket infection. No catheter‐related bloodstream infections, catheter thrombosis or occlusions, or catheter kinks occurred through 282 patient‐years. Two participants had adverse events of abdominal pain, rash, due to subcutaneous treprostinil “leaks” after one catheter puncture and one catheter laceration during pump refill and replacement, respectively. Eight pump failure events occurred: seven pump motor stalls and one early replacement (faulty battery).ConclusionDelivery of treprostinil with an intravascular delivery system is a safe alternative to an external delivery system, while providing enhanced life experiences. To preserve the risk–benefit ratio, treatment at specialized pulmonary arterial hypertension centers is recommended until training is disseminated at other sites.
Intersecting Identities and Patient Outcomes in Pulmonary Arterial Hypertension: Early Results in Derivation of a Model Using the Pulmonary Hypertension Association Registry (PHAR)
Grinnan, D. , Kang, Le , DeWilde, Christine , Johnson, D. , Allen, Roblee P., Badesch, David B., Bartolome, Sonja, Bull, T.M., Chakinala, Murali M. , DeMarco, Teresa , Elwing, Jean , Feldman, Jeremy P., Ford, H. James , Klinger, James R. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Ramani, Gautam , Robinson, Jeffrey C. , Runo, James , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, R.T., Benza, Raymond L. , Burger, Charles D. , Frantz, Robert P. , Hemnes, Anna R. , Horn, Evelyn M. , Lammi, Matthew R. , Rosenzweig, Erika B. , Simon, Marc A. , Thenappan, Thenappan , Ventetuolo, Corey E. , Williamson, Timothy L.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5098-A5098

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5098 Get It

Increasing Age Is Associated with Worsening Physical Function Despite More Favorable Cardiopulmonary Hemodynamics: A Pulmonary Hypertension Association Registry (PHAR) Report
Kime, Noah , Bartolome, Sonja, Badesch, David B., Bull, Todd M., Chakinala, Murali M. , Elwing, Jean , Feldman, Jeremy P., Fineman, Jeffrey R. , Grinnan, D. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Robinson, Jeffrey C. , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, Roham T. , Marco, Teresa De , Investigators, PHAR, DesJardin, Jacqueline T. , Kolaitis, Nicholas A , Kronmal, Richard A. , Benza, Raymond L. , Rosenzweig, Erika B. , Burger, Charles D. , Horn, Evelyn M. , Lammi, Matthew R. , Simon, Marc A. , Thenappan, Thenappan

Mayo Clinic

A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2516-A2516

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2516 Get It

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
Rahaghi, Franck , Alnuaimat, Hassan, Awdish, Rana , Balasubramanian, Vijay , Bourge, Robert C. , Butler, John, Cauthen, C. Gregory, Chakinala, Murali M. , deBoisblanc, Bennett P., Eggert, Michael, Engel, Peter A., Feldman, Jeremy, McConnell, J.W. , Park, Myung, Sager, Jeffrey S., Sood, Namita , Palevsky, Harold I. , Burger, Charles D.

Mayo Clinic

Pulmonary Circulation | July 17, 2017 | Volume: 7 | Issue: 3 | Pages: 702-711

10.1177/2045893217721695 | PMID 28671484 Get It

In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment‐related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add‐on therapy, drug–drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real‐world issues in using macitentan to treat patients with PAH.
Safety and Efficacy of Transition from Inhaled Treprostinil to Parenteral Treprostinil in Selected Patients with Pulmonary Arterial Hypertension
Feldman, Jeremy, Franco, Verónica , Ishizawar, David, Hill, Nicholas S. , Preston, Ioana R. , White, James , Burger, Charles D. , Waxman, Aaron B.

Mayo Clinic

Pulmonary Circulation | August 12, 2014 | Volume: 4 | Issue: 3 | Pages: 456-461

10.1086/677360 | PMID 25621159 Get It

Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add‐on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral treprostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty‐six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty‐four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18 μg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3–18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.